Clinical significance of circulating miRNA detection in lung cancer

Zhao, Chen; Lü, Fang; Chen, Hongxia; Zhao, Fen; Zhu, Ziwen; Zhao, Xianda; Chen, Honglei

doi:10.1007/s12032-016-0757-5

Cited by 32 publications

(24 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regulatory ncRNAs can be further divided into two groups based on their size: small ncRNAs (shorter than 200 nucleotides) and lncRNAs (200 nucleotides or longer). Small ncRNAs contain microRNAs, small nucleolar RNAs (snoRNAs), small interfering RNAs (siRNAs), small nuclear RNAs (snRNAs), and PIWI-interacting RNAs (piRNAs) (Figure 1) [49,50,51]. …”

Section: Non-coding Rnamentioning

confidence: 99%

“…MicroRNAs comprise one of the most abundant classes of gene regulatory molecules and therefore influence the output of many protein-coding genes [52]. MicroRNAs have the potential to serve as biomarkers and therapeutic tools for different cancer subtypes, as classified by origin, histology, aggressiveness, or chemosensitivity [37,38,39,40,45,46,47,48,49]. Importantly, in comparison to mRNAs, microRNAs are markedly less degraded in formalin-fixed paraffin-embedded (FFPE) samples, which are typically collected and stored in hospitals.…”

Section: Non-coding Rnamentioning

confidence: 99%

“…In recent years, the dysregulation of microRNAs and long non-coding RNAs (lncRNAs) has been highlighted as potential diagnostic and therapeutic tools in malignancies, including lung cancer [28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49]. Indeed, microRNAs and lncRNAs regulate a number of target genes, play an important role in lung carcinogenesis, and serve as potential diagnostic and therapeutic tools in lung cancer [37,38,39,40,41,42,43,44,45,46,47,48,49].…”

Section: Introductionmentioning

confidence: 99%

“…Indeed, microRNAs and lncRNAs regulate a number of target genes, play an important role in lung carcinogenesis, and serve as potential diagnostic and therapeutic tools in lung cancer [37,38,39,40,41,42,43,44,45,46,47,48,49]. …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Major Tumor Suppressor and Oncogenic Non-Coding RNAs: Clinical Relevance in Lung Cancer

Inamura

2017

Cells

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer deaths worldwide, yet there remains a lack of specific and sensitive tools for early diagnosis and targeted therapies. High-throughput sequencing techniques revealed that non-coding RNAs (ncRNAs), e.g., microRNAs and long ncRNAs (lncRNAs), represent more than 80% of the transcribed human genome. Emerging evidence suggests that microRNAs and lncRNAs regulate target genes and play an important role in biological processes and signaling pathways in malignancies, including lung cancer. In lung cancer, several tumor suppressor/oncogenic microRNAs and lncRNAs function as biomarkers for metastasis and prognosis, and thus may serve as therapeutic tools. In this review, recent work on microRNAs and lncRNAs is introduced and briefly summarized with a focus on potential biological and therapeutic applications.

show abstract

Section: Non-coding Rnamentioning

confidence: 99%

Section: Non-coding Rnamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Major Tumor Suppressor and Oncogenic Non-Coding RNAs: Clinical Relevance in Lung Cancer

Inamura

2017

Cells

View full text Add to dashboard Cite

show abstract

“…12 For this reason, CTCs can be used to predict the potential of distant metastases and prognosis of cancer patients. 13 Recently, a prospective multicenter study by Cohen et al 14 confirmed that the number of CTCs before and during treatment could be an independent predictor of progression-free survival (PFS) and overall survival (OS) in patients with mCRC. CTCs provided prognostic information in addition to that of imaging studies.…”

Section: Introductionmentioning

confidence: 99%

Circulating miR-1826 in plasma correlates with circulating tumor cells and is a prognostic marker in colorectal cancer

Han

et al. 2017

Tumour Biol.

View full text Add to dashboard Cite

Our previous study showed that miR-1826 was a newly identified oncogenic non-coding RNA in colorectal cancer. But the potential relationship between miR-1826 and tumor metastasis has not been fully elucidated. The purpose of this study was to evaluate the clinical significance of circulating miR-1826 and its possible associations with circulating tumor cells in colorectal cancer. Our results first found that serum miR-1826 was significantly upregulated in colorectal cancer patients, compared with that in healthy volunteers (p = 0.003). Similar results were also found in colorectal cancer with distant metastasis (p = 0.001) and advanced colorectal cancer (p < 0.001) patients, respectively. Clinicopathological analysis implied that circulating miR-1826 was positively associated with pT stage (p = 0.026), lymphatic metastasis (p = 0.034), distant metastasis (p = 0.012), and tumor-node-metastasis stage (p = 0.020). Besides, our univariate and multivariate analyses demonstrated that high serum miR-1826 expression could act as a prognostic and independent factor for overall survival of colorectal cancer patients (p < 0.05), which led to a poorer 5-year overall survival rate (p = 0.025). The area under the curve value of circulating miR-1826 was up to 0.848 ± 0.043, which strongly suggested serum miR-1826 as an effective diagnostic biomarker in colorectal cancer patients (p < 0.001). Our subsequent experiments demonstrated that patients with high level of circulating tumor cells showed a higher level of miR-1826 expression, compared with the circulating tumor cell-negative patients (p = 0.011). Similar results also showed that the amount of circulating tumor cells in high miR-1826 group was significantly higher than that in low miR-1826 group (p = 0.001). Furthermore, the relationship between serum miR-1826 and circulating tumor cells was analyzed using SPSS software and a significant logarithmic relationship was found, which meant that circulating miR-1826 closely correlated with the amount of circulating tumor cells in colorectal cancer patient serum (r = 0.283, p < 0.01). Our findings strongly suggested that serum miR-1826 could serve as an effective and non-invasive biomarker for diagnosis and prognosis of colorectal cancer. Circulating miR-1826 may be an important target in colorectal cancer therapy.

show abstract

Circulating microRNA biomarkers for lung cancer detection in Western populations

Guan

Ćuk

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

Lung cancer (LC) is a leading cause of cancer‐related death in the Western world. Patients with LC usually have poor prognosis due to the difficulties in detecting tumors at early stages. Multiple studies have shown that circulating miRNAs might be promising biomarkers for early detection of LC. We aimed to provide an overview of published studies on circulating miRNA markers for early detection of LC and to summarize their diagnostic performance in Western populations. A systematic literature search was performed in PubMed and ISI Web of Knowledge to find relevant studies published up to 11 August 2017. Information on study design, population characteristics, miRNA markers, and diagnostic accuracy (including sensitivity, specificity, and AUC) were independently extracted by two reviewers. Overall, 17 studies evaluating 35 circulating miRNA markers and 19 miRNA panels in serum or plasma were included. The median sensitivity (range) and specificity (range) were, respectively, 78.4% (51.7%‐100%) and 78.7% (42.9%‐93.5%) for individual miRNAs, and 83.0% (64.0%‐100%) and 84.9% (71.0%‐100%) for miRNA panels. Most studies incorporated individual miRNA markers as panels (with 2‐34 markers), with multiple miRNA‐based panels generally outperforming individual markers. Two promising miRNA panels were discovered and verified in prospective cohorts. Of note, both studies exclusively applied miRNA ratios when building up panels. In conclusion, circulating miRNAs may bear potential for noninvasive LC screening, but large studies conducted in screening or longitudinal settings are needed to validate the promising results and optimize the marker panels.

show abstract

Clinical significance of circulating miRNA detection in lung cancer

Cited by 32 publications

References 38 publications

Major Tumor Suppressor and Oncogenic Non-Coding RNAs: Clinical Relevance in Lung Cancer

Major Tumor Suppressor and Oncogenic Non-Coding RNAs: Clinical Relevance in Lung Cancer

Circulating miR-1826 in plasma correlates with circulating tumor cells and is a prognostic marker in colorectal cancer

Circulating microRNA biomarkers for lung cancer detection in Western populations

Contact Info

Product

Resources

About